Physician profile
Peter Samuel Abadeer
NPI 1760469522
$16,843.79
in general payments reported to CMS, 2019-2025
53 companies · $3,065 in 2025
The $3,065 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,114 · 2020: $1,208 · 2021: $2,085 · 2022: $2,435 · 2023: $2,989 · 2024: $2,947 · 2025: $3,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,992 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,992.17 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,056.19 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,509.83 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $1,143.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,133.54 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $1,080.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,011.81 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $870.40 | 2019-2025 | |
| Lilly USA, LLC | $823.16 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $661.53 | 2022-2025 | |
| Astellas Pharma US INC | $514.79 | 2019-2025 | Veozah |
| Dexcom, INC. | $451.23 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $439.38 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $398.66 | 2019-2025 | Repatha, Prolia, Evenity |
| Kowa Pharmaceuticals America, INC. | $378.83 | 2019-2025 | Livalo, Zoryve, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $376.35 | 2020-2024 | Eliquis, Camzyos |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Abadeer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.